Results 161 to 170 of about 142,003 (296)

Organoid Coculture Models for Cancer Research and Immunotherapy

Med Research, EarlyView.
This review summarizes organoid coculture platforms, including submerged Matrigel culture, air–liquid interface, microfluidic/organoid‐on‐a‐chip, and 3D bioprinting, for reconstructing the tumor microenvironment to study tumor–stroma/immune crosstalk, evaluate immunotherapies, and enable drug screening.
Zhuo Yang, Huihui Yang, Guangxin Li, Guobang Liu, Zhulan Chen, Wenzhi Tian, Meiyang Huang, Xiaoling Liu, Yongsheng Zhao, Dong Chen   +9 more
wiley   +1 more source

RETRACTION: Comparison Efficacy and Safety of Gemcitabine plus Cisplatin and 5-Fluorouracil plus Cisplatin for Metastatic Nasopharyngeal Carcinoma: A Meta-Analysis and Systematic Review. [PDF]

J Oncol
Oncology JO.
europepmc   +1 more source

The efficacy of concurrent chemoradiotherapy with or without nimotuzumab in high‐risk patients with locally advanced head and neck squamous cell carcinoma post‐surgery: A real‐world study

Precision Radiation Oncology, EarlyView.
Figure 1 Patient selection flowchart. CCRT, concurrent chemoradiotherapy; NCCRT, nimotuzumab and concurrent chemoradiotherapy. Abstract Purpose Patients with locally advanced head and neck squamous cell carcinoma (LA‐HNSCC) harboring high‐risk pathological features after radical surgery face high recurrence rates.
Yuejia Zhou, Linting Zhang, Wenjuan Lai, Jingyun Tan, Jing Gao, Yajie Liu, Shubin Wang, Feng Peng, Gangling Tong   +8 more
wiley   +1 more source

Retraction Note: Enhanced antitumor efficacy in colon cancer using EGF functionalized PLGA nanoparticles loaded with 5-Fluorouracil and perfluorocarbon. [PDF]

BMC Cancer
Wu P, Zhou Q, Zhu H, Zhuang Y, Bao J.
europepmc   +1 more source

Mechanistic Learning for Predicting Survival Outcomes in Head and Neck Squamous Cell Carcinoma

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 540-550, March 2025.
ABSTRACT We employed a mechanistic learning approach, integrating on‐treatment tumor kinetics (TK) modeling with various machine learning (ML) models to address the challenge of predicting post‐progression survival (PPS)—the duration from the time of documented disease progression to death—and overall survival (OS) in Head and Neck Squamous Cell ...
Kevin Atsou, Anne Auperin, Jôel Guigay, Sébastien Salas, Sebastien Benzekry   +4 more
wiley   +1 more source

Oxaliplatin-induced autoimmune-like hepatitis: A case report highlighting the role of clinical pharmacists. [PDF]

Biomed Rep
Zeng X, Liu T, Jin G.
europepmc   +1 more source

Dehydrocostus Lactone Suppresses Hepatocellular Carcinoma by Inhibiting Protein Tyrosine Kinase‐7 Mediated β‐Catenin Signaling

Phytotherapy Research, EarlyView.
Schematic summary of the experimentally supported mechanism of DHL in hepatocellular carcinoma. Dehydrocostus lactone (DHL), a sesquiterpene lactone derived from Aucklandia lappa, directly engages protein tyrosine kinase 7 (PTK7), as supported by molecular docking, CETSA, and DARTS assays.
Xiwen Fan, Junhui Li, Yu Qiao, Yuwen Zhong, Xuecheng Ge, Yaoshuai Zhang, Zishu Wang, Feng Qian, Weixin Ren   +8 more
wiley   +1 more source

Exploring the occupational protection potential of an intravenous compounding robot across the cytotoxic drug workflow. [PDF]

Front Public Health
Sun J, Liu B, Li Z, Hu R, Bai S.
europepmc   +1 more source

Schisandrin C Targets PPARγ to Induce Ferroptosis in Colorectal Cancer Cells and Promote M1 Macrophage Polarization

Phytotherapy Research, EarlyView.
Schisandrin C: A Dual Anti‐Colorectal Cancer Strategy Targeting PPARγ. ABSTRACT Colorectal cancer (CRC) remains a leading cause of cancer mortality, necessitating novel therapeutic strategies. Schisandrin C (SinC), a bioactive lignan from Schisandra chinensis, exhibits diverse pharmacological activities, but its anti‐CRC mechanisms are poorly ...
Xiao Wei, Hong‐Ping Wen, Jian‐Bo Song, Jin‐Fang Xu, Hong‐Rui Guo   +4 more
wiley   +1 more source

Avatrombopag Versus Placebo for Persistent Chemotherapy-Induced Thrombocytopenia in GI Cancers: The Phase II ACT-GI Trial. [PDF]

J Clin Oncol
Al-Samkari H, Shatzel JJ, Panch SR, Keating JH, Walsh EP, Weekes CD, Kardosh A, Cohen SA, Cohen JJ, Hodges PG, Dhaver SE, Strojny N, Donovan C, Belibasakis C, Soff GA.   +14 more
europepmc   +1 more source